A completed acquisition, an AI platform launch, cancer immunotherapy research and laboratory milestones highlight five companies pursuing different paths toward growth.
DALLAS, Texas, October 13, 2026 Alaunos Therapeutics (NASDAQ: TCRT), IGC Pharma (NYSE American: IGC), PDS Biotechnology (NASDAQ: PDSB), Pinnacle Food Group (NASDAQ: PFAI) and VivoSim Labs (NASDAQ: VIVS) are advancing initiatives across cardiopulmonary disease, Alzheimer’s care, cancer immunotherapy, recombinant protein production and predictive toxicology.
The developments bring distinct milestones into focus, from expanding therapeutic pipelines and evaluating commercial AI applications to demonstrating manufacturing scalability and broader pharmaceutical adoption.
Alaunos Therapeutics: Velaris Acquisition Expands Cardiopulmonary Pipeline
Alaunos Therapeutics, Inc. (NASDAQ: TCRT) announced the completion of its acquisition of Velaris Therapeutics, Inc., a privately held biotechnology company developing potential treatments for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases.
The acquisition adds a portfolio of ActRII-Fc ligand traps and complementary biologics designed to address signaling imbalances that contribute to pulmonary vascular remodeling. For investors, the transaction introduces a new therapeutic development direction, with integration, candidate advancement and future clinical milestones providing measures of progress.
IGC Pharma: PRISM Connects Alzheimer’s AI With Potential Commercial Applications
IGC Pharma, Inc. (NYSE American: IGC) introduced PRISM, an application layer designed to bring its patent-pending MINT-AD Alzheimer’s AI platform closer to practical healthcare use.
PRISM targets early risk stratification, cognitive health tracking, clinical-trial optimization and personalized brain-health programs. It is designed to translate AI-generated risk insights into structured workflows supporting assessment, ongoing monitoring and patient engagement.
IGC is evaluating B2B, B2B2C and online commercialization opportunities, with potential users including healthcare providers, memory clinics, pharmaceutical companies, clinical research organizations and consumer brain-health platforms. The launch expands its AI strategy, while deployment agreements, validation and revenue generation remain developments to watch.
PDS Biotechnology: Cancer Research Adds Clinical and Peer-Reviewed Visibility
PDS Biotechnology Corporation (NASDAQ: PDSB) announced an upcoming virtual expert event featuring Jonathan M. Hernandez, M.D., of the National Cancer Institute, to discuss PDS0301 Phase 2 clinical outcomes in advanced liver-associated cancers, particularly metastatic colorectal cancer.
The discussion will address patients with previously treated, unresectable microsatellite-stable or mismatch repair-proficient colorectal liver metastases, a population in which immunotherapy has generally shown limited effectiveness. PDS0301 is an investigational IL-12 immunocytokine designed to deliver immune stimulation within tumors.
Separately, PDS reported publication of its VERSATILE-002 Phase 2 results evaluating PDS0101 plus pembrolizumab in HPV16-positive recurrent or metastatic head and neck cancer in the September 17, 2026, issue of JAMA Oncology. These developments provide additional visibility into two distinct investigational programs.
Pinnacle Food Group: Fermentation Milestone Advances Recombinant Protein Development
Pinnacle Food Group (NASDAQ: PFAI) reported that its subsidiary, Pinnacle Food AgTech HK, completed its first bench-scale fermentation of a yeast strain designed to produce recombinant human lactoferrin (rhLF).
The experiment used a 5-liter fermenter and methanol-free Pichia technology developed through its research collaboration with Bioboost Synbio Consulting. Laboratory testing supported confirmation of target-protein expression.
Lactoferrin is an iron-binding protein used in nutritional products and supplements. The milestone supports further process development, although commercial potential depends on yield, purification, biological characterization, production economics and applicable regulatory requirements. Bench-scale expression does not yet establish commercial manufacturing capability.
VivoSim Labs: Human Tissue Models Target Drug-Testing Demand
VivoSim Labs, Inc. (NASDAQ: VIVS) is positioning its NAMkind™ 3D human tissue models and VitroSense™ AI predictive toxicology platform around the FDA’s expanding interest in New Approach Methodologies (NAMs) that can reduce reliance on animal testing.
The company reported 91% predictive accuracy, 90% sensitivity and 95% specificity for its NAMkind™ Liver model across a 92-compound dataset. VitroSense™ separately reported up to 96% accuracy predicting potential drug-induced diarrhea.
VivoSim is also developing a rat liver model to help assess whether animal toxicity findings may translate to humans. Model validation, pharmaceutical adoption and potential use in regulatory submissions are milestones to monitor; the company has not announced FDA qualification of NAMkind™.
About the Companies
Alaunos Therapeutics develops investigational therapies, including its acquired cardiopulmonary pipeline. IGC Pharma advances Alzheimer’s therapeutics and AI-enabled healthcare technologies. PDS Biotechnology develops cancer immunotherapies. Pinnacle Food Group is pursuing food biotechnology and recombinant protein production. VivoSim Labs develops tissue models and predictive toxicology tools for drug development.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com